文献速递类风湿关节炎

托珠单抗与其他生物制剂治疗类风湿关节炎的恶性肿瘤风险:多数据库队列研究

Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study.
PubMed 文献 · Semin Arthritis Rheum · 2019-03-09

该多数据库队列研究纳入三个美国保险索赔数据库,比较托珠单抗与TNF抑制剂或阿巴西普新使用者中排除非黑色素瘤皮肤癌的恶性肿瘤发生率。结果显示托珠单抗与TNF抑制剂(合并HR 0.98,95%CI 0.80-1.19)及阿巴西普(合并HR 0.97,95%CI 0.74-1.27)的恶性肿瘤风险相似。

要点

  • 托珠单抗与TNF抑制剂相比,排除NMSC的恶性肿瘤风险相似(HR 0.98)。
  • 托珠单抗与阿巴西普相比,恶性肿瘤风险亦相似(HR 0.97)。
  • 三个数据库的恶性肿瘤发生率范围在托珠单抗组为8.27至23.18/1000人年。

核心结论

  • 在类风湿关节炎患者中,新开始托珠单抗治疗与TNF抑制剂或阿巴西普相比,排除非黑色素瘤皮肤癌的恶性肿瘤风险无差异。

研究设计与样本

  • 多数据库队列研究,使用美国Medicare(2010-2015)、IMS PharMetrics Plus(2011-2015)和Truven MarketScan(2011-2015)三个保险索赔数据库。
  • 纳入成年类风湿关节炎患者,既往失败于另一种TNF抑制剂、阿巴西普或托法替尼后新开始托珠单抗或TNF抑制剂。
  • 托珠单抗启动者按倾向评分以可变比例1:3匹配至TNF抑制剂启动者,各数据库内匹配。
  • 三个倾向评分匹配队列的风险比通过逆方差加权固定效应模型合并。
  • 次要分析比较托珠单抗启动者与阿巴西普启动者。

主要发现

  • 共纳入13,102例托珠单抗启动者,倾向评分匹配至26,727例TNF抑制剂启动者(三个数据库合计)。
  • 托珠单抗组恶性肿瘤发病率范围为8.27(IMS)至23.18(Medicare)/1000人年。
  • TNF抑制剂组恶性肿瘤发病率范围为9.64(MarketScan)至21.46(Medicare)/1000人年。
  • 托珠单抗与TNF抑制剂相比,恶性肿瘤风险相似,合并HR为0.98(95%CI 0.80-1.19)。
  • 次要分析托珠单抗与阿巴西普相比,合并HR为0.97(95%CI 0.74-1.27)。

关键数值与推荐

  • 主要结局为排除非黑色素瘤皮肤癌的任何恶性肿瘤的发生。

临床怎么用

  • 在类风湿关节炎患者中选用托珠单抗时,其恶性肿瘤风险与TNF抑制剂或阿巴西普相当,无需因恶性肿瘤风险差异而优先选择其他生物制剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To examine the rate of incident malignancies excluding non-melanoma skin cancer (NMSC) in patients with rheumatoid arthritis (RA) newly treated with tocilizumab versus other biologic drugs. METHODS: We conducted a cohort study using data from 3 U.S. insurance claims databases - Medicare (2010-2015), 'IMS' PharMetrics Plus (2011-2015) and Truven 'MarketScan' (2011-2015). Adults with RA who newly started tocilizumab or a TNF inhibitor (TNFi) after failing a different TNFi, abatacept or tofacitinib were included. The primary outcome was development of any malignancies excluding NMSC. For confounding control, tocilizumab starters were propensity score (PS)-matched to TNFi starters with a variable ratio of 1:3 within each database. Hazard ratios (HR) from the 3 PS-matched cohorts were combined by an inverse variance-weighted, fixed-effects model. We conducted a secondary analysis where we compared tocilizumab initiators with abatacept initiators. RESULTS: We included 13,102 tocilizumab initiators PS-matched to 26,727 TNFi initiators in all three databases. The incidence rate of malignancies per 1,000 person-years ranged from 8.27 (IMS) to 23.18 (Medicare) in the tocilizumab group and from 9.64 (MarketScan) to 21.46 (Medicare) in the TNFi group. The risk of incident malignancies was similar between tocilizumab and TNFi initiators across all three databases, with a combined HR of 0.98 (95%CI 0.80-1.19) in tocilizumab versus TNFi. The secondary analysis comparing tocilizumab versus abatacept showed similar results (combined HR 0.97, 95%CI 0.74-1.27). CONCLUSIONS: This large multi-database cohort study found no difference in the risk of malignancies excluding NMSC in RA patients who newly started tocilizumab compared with TNFi or abatacept.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Kim SC, Pawar A, Desai RJ, et al. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study. Semin Arthritis Rheum. 2019. PMID: 30967248. doi:10.1016/j.semarthrit.2019.03.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。